Table 7 Overview of the impact of varying the efficacy against CIN2+ outcomes associated with non-vaccine types
Cross protection efficacy (%) | Difference in cross-protection efficacy | Difference in undiscounted lifetime cases of cancer | Difference in discounted lifetime healthcare cost | Difference in discounted lifetime QALY | Discounted incremental cost per QALY Gained |
|---|---|---|---|---|---|
|  | (A – B) | (A – B) | (A – B) | (A – B) |  |
A: 45.7; B: 51.9 | −6.2 | 8 | $628 335 | −115 | B Dominates A |
A: 45.7; B: 32.5 | 13.2 | −18 | $28 868 | −62 | B Dominates A |
A: 68.4; B: 51.9 | 16.5 | −22 | -$83 640 | −52 | $1 611 |
A: 82.4; B: 51.9 | 30.5 | −42 | -$530 970 | −12 | $43 499 |
Base Case: A: 68.4; B: 32.5 | 35.9 | −48 | -$683 107 | 1 | A Dominates B |
A: 45.7; B: 6.0 | 39.7 | −52 | -$771 520 | 10 | A Dominates B |
A: 82.4; B: 32.5 | 49.9 | −67 | -$1 130 437 | 41 | A Dominates B |
A: 68.4; B: 6.0 | 62.4 | −83 | -$1 483 495 | 73 | A Dominates B |
A: 82.4; B: 6.0 | 76.4 | −102 | -$1 930 825 | 113 | A Dominates B |